---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-021578"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:41:38.841582+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Senti Bio FY2025 net loss $61.4M; SENTI-202 gets RMAT, Phase 1 data encouraging

## Summary
- Net loss $61.4M for FY2025 ($2.73/share); Q4 loss $14.5M ($0.53/share).
- Cash and equivalents $16.4M as of December 31, 2025.
- SENTI-202 received RMAT designation for relapsed/refractory AML; updated Phase 1 data show encouraging responses and safety.
- R&D expenses $37.6M full year; G&A expenses $26.2M full year, down in Q4 YoY.

## SEC filing metadata
- accession: 0001628280-26-021578
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/0001628280-26-021578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/snti-20260327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-021578
- JSON: https://secwatch.observer/filing/0001628280-26-021578.json
- Plain text: https://secwatch.observer/filing/0001628280-26-021578.txt

## Key facts
- Earnings Releases
  Senti Biosciences, Inc. reported the year ended December 31, 2025 results: net income Net loss ... for the full-year 2025 was $61.4 million, or $2.73 per share, EPS $2.73 per share.
  - Period: the year ended December 31, 2025
  - Net income: Net loss ... for the full-year 2025 was $61.4 million, or $2.73 per share
  - EPS: $2.73 per share
  - Result: reported results
  source text: Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/0001628280-26-021578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.